^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + BMS-202 (PD1 inhibitor, PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
Published date:
12/21/2022
Excerpt:
BMS-202 causes dose-dependent growth inhibition of HER2+ BC cell colonies alone, while this effect is significantly improved when used in combination with TZ….We first examined the outcome of TZ and BMS-202 on the viability of ZR75; a HER2+ BC cell line. A significant decrease in the viability of ZR75 cells was observed after mono-treatment with TZ (20µg/mL) and BMS-202 (10µM). Interestingly, combining both treatments resulted in a more significant reduction of cell viability....Our mathematical model-based study points out that the combination therapy using trastuzumab (anti-HER2, mAb) and BMS-202 (anti-PD-1/PD-L1, SmI) results in a significant growth inhibition of HER2+ BC cell lines compared with monotherapies...
DOI:
https://doi.org/10.3389/fonc.2022.977664
